MedTrace Logo

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

NCT05266417 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2026-03-31

No results posted yet for this study

Summary

This study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo.

Conditions

  • Parkinson Disease

Interventions

DRUG

INS-GSH

Intranasal INS-GSH Twice Daily

DRUG

Matched Placebos

Intranasal Matched Placebos Twice Daily

Sponsors & Collaborators

  • Gateway Institute for Brain Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-07
Primary Completion
2027-01-01
Completion
2027-07-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05266417 on ClinicalTrials.gov